---
title: "SONOSCAPE released its 2024 annual performance, with a net profit attributable to the parent company of 142 million yuan, a year-on-year decrease of 68.67%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/235581011.md"
description: "SONOSCAPE released its 2024 annual report, with operating revenue of 2.014 billion yuan, a year-on-year decrease of 5.02%; net profit attributable to the parent company of 142 million yuan, a year-on-year decrease of 68.67%; net profit excluding non-recurring gains and losses of 110 million yuan, a year-on-year decrease of 75.07%. The basic earnings per share are 0.33 yuan, and it plans to distribute a cash dividend of 1 yuan (including tax) for every 10 shares to all shareholders"
datetime: "2025-04-11T09:41:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/235581011.md)
  - [en](https://longbridge.com/en/news/235581011.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/235581011.md)
generator: "portal-rs"
---

# SONOSCAPE released its 2024 annual performance, with a net profit attributable to the parent company of 142 million yuan, a year-on-year decrease of 68.67%

According to the Zhitong Finance APP, SONOSCAPE (300633.SZ) released its annual report for 2024. During the reporting period, the company achieved operating revenue of 2.014 billion yuan, a year-on-year decrease of 5.02%. The net profit attributable to shareholders of the listed company was 142 million yuan, a year-on-year decrease of 68.67%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 110 million yuan, a year-on-year decrease of 75.07%. The basic earnings per share were 0.33 yuan. It is proposed to distribute a cash dividend of 1 yuan (including tax) for every 10 shares to all shareholders

### Related Stocks

- [300633.CN](https://longbridge.com/en/quote/300633.CN.md)

## Related News & Research

- [SynAct Pharma bolsters resomelagon data as it readies Phase 3 and weighs strategic deals](https://longbridge.com/en/news/298195637.md)
- [Grass Valley showcases new Framelight X workflow capabilities at IBC2026](https://longbridge.com/en/news/298178097.md)
- [Cyclezyme to buy Ragn-Sells melanin patent, pays via shares for 7.9% stake](https://longbridge.com/en/news/298137821.md)
- [Public Relations Portal Introduces Subscription-Based Platform for Recurring Media Placements](https://longbridge.com/en/news/298200631.md)
- [22:00 ETCarestream Healthcare International améliore le détecteur DRX-LC pour améliorer les performances d'imagerie de grande longueur](https://longbridge.com/en/news/297978656.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**